S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 07:15 AM ET

ZYBT

Zhengye Biotechnology Holding Limited

Price Chart
Latest Quote

$0.70

-0.06 (-7.55%)
Current Price
Previous Close $0.76
Open $0.71
Day High $0.76
Day Low $0.70
Volume 2,309
Fetched: 2026-07-18T11:15:28
Stock Information
Note: Financial values converted from CNY to USD
Shares Outstanding 47.39M
Total Debt $11.08M
Cash Equivalents $7.66M
Revenue $17.17M
Net Income $-10.30M
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Market Cap $33.08M
EPS (TTM) $-0.22
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$113.14M
Sales$17.17M
Income$-10.30M
Book/sh$0.91
Cash/sh$1.09
Employees269
Financial Ratios
Quick Ratio0.58
Current Ratio1.14
Debt/Eq24.48
Returns & Margins
ROA-9.48%
ROE-25.17%
Gross Margin20.51%
Operating Margin-77.04%
Profit Margin-59.97%
Ownership
Insider Ownership16.16%
Institutional Ownership1.10%
Insider & Institutional transactions data not available
Valuation Ratios
P/S0.28
P/B0.76
Analyst Data
Recommendationnone
Technical Indicators
SMA20$0.73
SMA50$0.82
SMA200$1.33
RSI48.04
ATR0.0682
Shares Float6.26M
Short Float0.10%
Short Ratio0.24
Rel Volume0.04
Performance History
Week-10.51%
Month-17.20%
Quarter-32.23%
6 Months-37.68%
YTD-38.23%
Year-87.10%
10 Years-85.64%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-07-17 $0.70 2,300
2026-07-16 $0.75 1,900
2026-07-15 $0.75 5,900
2026-07-14 $0.71 19,800
2026-07-13 $0.70 8,200
2026-07-10 $0.78 5,800
2026-07-09 $0.77 25,300
2026-07-08 $0.77 24,200
2026-07-07 $0.77 92,600
2026-07-06 $0.70 799,100
2026-07-02 $0.65 21,300
2026-07-01 $0.68 7,100
2026-06-30 $0.68 4,400
2026-06-29 $0.69 7,200
2026-06-26 $0.71 16,200
2026-06-25 $0.76 29,400
2026-06-24 $0.77 24,800
2026-06-23 $0.78 44,700
2026-06-22 $0.72 26,500
2026-06-18 $0.75 8,300
About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $13,686,647 $14,066,647 $13,930,806 $16,630,905
Cost Of Revenue $13,686,647 $14,066,647 $13,930,806 $16,630,905
Total Revenue $17,218,661 $27,576,020 $31,319,046 $38,513,292
Operating Revenue $15,185,633 $25,643,319 $30,238,533 $37,286,728
Expenses
Interest Expense $503,115 $598,263 $654,493 $420,101
Total Expenses $27,318,543 $25,034,994 $24,269,667 $28,733,776
Other Income Expense $-46,612 $153,006 $34,626 $81,386
Other Non Operating Income Expenses $-19,237 $21,604 $34,626 $81,386
Net Non Operating Interest Income Expense $-488,909 $-564,081 $-608,325 $-403,232
Interest Expense Non Operating $503,115 $598,263 $654,493 $420,101
Operating Expense $13,631,896 $10,968,347 $10,338,862 $12,102,871
Other Operating Expenses $-333,240 $-108,466 $-392,578 $-37,734
Selling And Marketing Expense $6,498,764 $6,106,778 $6,028,943 $5,114,754
General And Administrative Expense $4,588,111 $3,340,534 $3,491,025 $3,598,899
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-10,326,284 $1,673,745 $4,654,848 $6,915,609
Net Interest Income $-488,909 $-564,081 $-608,325 $-403,232
Interest Income $14,206 $34,182 $46,168 $16,869
Normalized Income $-10,305,752 $1,550,753 $4,654,848 $6,915,609
Net Income From Continuing And Discontinued Operation $-10,326,284 $1,673,745 $4,654,848 $6,915,609
Total Operating Income As Reported $-10,433,122 $2,432,560 $6,656,801 $9,741,783
Net Income Common Stockholders $-10,326,284 $1,673,745 $4,654,848 $6,915,609
Net Income $-10,326,284 $1,673,745 $4,654,848 $6,915,609
Net Income Including Noncontrolling Interests $-12,277,186 $1,993,223 $5,550,392 $8,248,420
Net Income Continuous Operations $-12,277,186 $1,993,223 $5,550,392 $8,248,420
Pretax Income $-10,635,404 $2,129,951 $6,475,680 $9,457,671
Interest Income Non Operating $14,206 $34,182 $46,168 $16,869
Operating Income $-10,099,882 $2,541,026 $7,049,379 $9,779,516
Gross Profit $3,532,014 $13,509,373 $17,388,240 $21,882,388
Special Income Charges - - $-1,486,852 $-143,240
Per Share
Diluted EPS - $0.04 $0.10 $0.15
Basic EPS - $0.04 $0.10 $0.15
Other
Tax Effect Of Unusual Items $-6,844 $8,410 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-6,264,224 $6,172,331 $10,668,550 $12,659,701
Total Unusual Items $-27,375 $131,402 $-1,486,852 $-143,240
Total Unusual Items Excluding Goodwill $-27,375 $131,402 $-1,486,852 $-143,240
Reconciled Depreciation $3,840,690 $3,575,519 $3,538,377 $2,781,929
EBITDA (Bullshit earnings) $-6,291,599 $6,303,733 $10,668,550 $12,659,701
EBIT $-10,132,289 $2,728,214 $7,130,173 $9,877,772
Diluted NI Availto Com Stockholders $-10,326,284 $1,673,745 $4,654,848 $6,915,609
Minority Interests $1,950,902 $-319,478 $-895,544 $-1,332,810
Tax Provision $1,641,782 $136,729 $925,287 $1,209,251
Gain On Sale Of Security $-27,375 $131,402 - -
Provision For Doubtful Accounts $212,788 $-263,691 $-549,579 $1,440,536
Research And Development $2,665,473 $1,893,192 $1,761,050 $1,986,416
Selling General And Administration $11,086,875 $9,447,313 $9,519,968 $8,713,653
Other Gand A $4,588,111 $3,340,534 $3,491,025 $3,598,899
Diluted Average Shares - $6,979,442 $6,979,442 $6,979,442
Basic Average Shares - $6,979,442 $6,757,480 $6,757,480
Write Off - - $1,486,852 $143,240
Fetched: 2026-07-15
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $28,868,581 $38,647,949 $36,751,946 $39,745,184
Total Assets $64,586,922 $72,988,200 $73,970,902 $76,898,734
Total Non Current Assets $44,252,205 $46,712,880 $45,967,974 $45,186,519
Non Current Prepaid Assets $1,037,896 $2,766,836 $962,429 $330,576
Non Current Deferred Assets $0 $2,817,295 $2,428,417 -
Non Current Deferred Taxes Assets $0 $1,626,393 $1,762,974 -
Goodwill And Other Intangible Assets $8,102,664 $3,370,869 $3,623,019 $4,128,945
Other Intangible Assets $8,102,664 $3,370,869 $3,623,019 $4,128,945
Current Assets $20,334,718 $26,275,320 $28,002,928 $31,712,216
Other Current Assets $1,002,382 $2,871,010 - -
Restricted Cash $296 $296 $1,792,421 $0
Prepaid Assets $3,122,419 $-776,868 $460,202 $360,023
Inventory $5,795,587 $8,615,102 $8,626,940 $8,201,364
Receivables $2,735,317 $12,600,807 $14,711,818 $19,865,637
Notes Receivable $0 $3,786,975 $3,435,238 $4,539,723
Accounts Receivable $2,735,317 $8,813,832 $10,974,710 $15,226,474
Allowance For Doubtful Accounts Receivable $-2,668,580 $-2,496,929 $-2,754,702 $-3,163,261
Gross Accounts Receivable $5,403,897 $11,310,761 $13,729,412 $18,389,735
Cash Cash Equivalents And Short Term Investments $7,678,716 $2,964,974 $2,411,548 $1,442,164
Cash And Cash Equivalents $7,447,875 $2,752,926 $2,230,426 $1,442,164
Cash Financial $7,447,875 $2,752,926 $2,230,426 $1,442,164
Other Receivables - $388,582 $192,663 $99,439
Current Deferred Assets - - $2,428,417 $1,843,028
Current Deferred Taxes Assets - - $1,762,974 $1,843,028
Debt
Net Debt $3,598,455 $10,036,993 $11,065,123 $8,158,451
Total Debt $11,110,403 $12,789,919 $13,295,549 $9,600,615
Long Term Debt And Capital Lease Obligation $1,357,966 $710,280 $1,478,270 $1,478,270
Long Term Debt $1,309,578 $710,280 $1,478,270 $1,478,270
Current Debt And Capital Lease Obligation $9,752,437 $12,079,639 $11,817,280 $8,122,345
Current Debt $9,736,752 $12,079,639 $11,817,280 $8,122,345
Other Current Borrowings $103,582 $1,063,940 $11,817,280 $8,122,345
Liabilities
Total Liabilities Net Minority Interest $19,200,786 $20,821,111 $23,767,145 $24,091,358
Total Non Current Liabilities Net Minority Interest $1,373,356 $710,280 $1,536,424 $1,565,575
Non Current Deferred Liabilities $15,389 $0 - -
Non Current Deferred Taxes Liabilities $15,389 $0 - -
Current Liabilities $17,827,430 $20,110,832 $22,230,721 $22,525,783
Other Current Liabilities $58,746 $82,274 $124,447 $131,106
Current Deferred Liabilities $714,275 $947,928 $589,680 $695,630
Payables And Accrued Expenses $7,301,972 $7,000,991 $9,699,314 $13,576,702
Payables $7,228,428 $6,986,341 $9,697,834 $13,575,222
Other Payable $369,050 $302,017 $285,740 $365,202
Total Tax Payable $347,001 $305,716 $339,603 $1,479,158
Accounts Payable $6,512,378 $6,357,004 $6,756,388 $11,730,862
Tradeand Other Payables Non Current - $0 $58,154 $87,305
Dividends Payable - $0 $2,316,104 $0
Equity
Common Stock Equity $36,971,245 $42,018,819 $40,374,965 $43,874,129
Total Equity Gross Minority Interest $45,386,137 $52,167,089 $50,203,757 $52,807,376
Stockholders Equity $36,971,245 $42,018,819 $40,374,965 $43,874,129
Gains Losses Not Affecting Retained Earnings $4,545,938 $4,831,382 $4,633,244 $4,078,929
Other Equity Adjustments $4,545,938 $4,831,382 $4,633,244 $4,078,929
Retained Earnings $-3,201,142 $7,125,142 $5,679,427 $9,732,904
Other
Ordinary Shares Number $7,012,736 $6,979,442 $6,979,442 $6,979,442
Share Issued $7,012,736 $6,979,442 $6,979,442 $6,979,442
Tangible Book Value $28,868,581 $38,647,949 $36,751,946 $39,745,184
Invested Capital $48,017,575 $54,808,738 $53,670,514 $53,474,744
Working Capital $2,507,288 $6,164,488 $5,772,207 $9,186,433
Capital Lease Obligations $64,073 $0 - -
Total Capitalization $38,280,824 $42,729,099 $41,853,235 $45,352,399
Minority Interest $8,414,891 $10,148,270 $9,828,792 $8,933,248
Additional Paid In Capital $35,625,265 $30,061,111 $30,061,111 $30,061,111
Capital Stock $1,184 $1,184 $1,184 $1,184
Common Stock $1,184 $1,184 $1,184 $1,184
Long Term Capital Lease Obligation $48,388 $0 - -
Current Deferred Revenue $714,275 $545,288 $589,680 $695,630
Current Capital Lease Obligation $15,685 $0 - -
Line Of Credit $9,633,169 $11,015,699 $11,817,280 -
Current Accrued Expenses $73,544 $14,650 $1,480 $1,480
Dueto Related Parties Current $0 $21,604 $0 -
Net PPE $35,111,644 $37,757,880 $38,954,110 $40,726,998
Accumulated Depreciation $-19,499,399 $-16,507,050 $-13,702,628 $-10,864,617
Gross PPE $54,611,043 $54,264,930 $52,656,738 $51,591,614
Construction In Progress $90,265 $1,443,052 $1,126,977 $12,143,416
Other Properties $21,904,584 $21,938,914 $21,864,779 $21,231,150
Machinery Furniture Equipment $485,358 $485,210 $485,210 $491,277
Buildings And Improvements $32,130,837 $30,397,754 $29,179,772 $17,725,771
Properties $0 $0 $0 $0
Finished Goods $2,003,877 $2,624,632 $2,198,760 $2,069,282
Work In Process $2,617,529 $4,891,164 $4,967,963 $5,015,463
Raw Materials $1,174,181 $1,099,306 $1,460,217 $1,613,815
Duefrom Related Parties Current $0 $0 $109,206 $0
Other Short Term Investments $230,841 $212,048 $181,121 $0
Land And Improvements - - $1,902,958 $1,902,958
Inventories Adjustments Allowances - - $-1,980,941 $-497,196
Fetched: 2026-07-15
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $104,026 $1,964,072 $5,413,516 $-1,478,714
Operating Activities
Operating Cash Flow $1,972,950 $6,073,780 $7,130,025 $2,565,146
Cash Flow From Continuing Operating Activities $1,972,950 $6,073,780 $7,130,025 $2,565,146
Operating Gains Losses $46,168 $-74,727 $27,671 -
Investing Activities
Capital Expenditure $-1,868,924 $-4,109,708 $-1,716,509 $-4,043,859
Investing Cash Flow $-1,868,924 $-4,093,727 $-1,740,925 $-4,043,859
Cash Flow From Continuing Investing Activities $-1,868,924 $-4,093,727 $-1,740,925 $-4,043,859
Financing Activities
Issuance Of Capital Stock $6,374,761 $0 $0 -
Financing Cash Flow $4,781,071 $-3,274,538 $-2,808,417 $1,991,003
Cash Flow From Continuing Financing Activities $4,781,071 $-3,274,538 $-2,808,417 $1,991,003
Net Other Financing Charges $195,919 $-498,380 $-665,443 -
Cash Dividends Paid $0 $-2,371,003 $-5,837,908 $-3,170,363
Common Stock Dividend Paid $0 $-2,371,003 $-5,837,908 $-3,170,363
Net Common Stock Issuance $6,374,761 $0 $0 -
Common Stock Issuance $6,374,761 $0 $0 -
Other
Repayment Of Debt $-12,217,108 $-13,740,954 $-8,122,345 $-9,614,228
Issuance Of Debt $10,427,499 $13,335,798 $11,817,280 $14,775,595
Interest Paid Supplemental Data $496,604 $589,680 $654,493 $420,101
Income Tax Paid Supplemental Data $0 $17,165 $1,551,665 $1,254,976
End Cash Position $7,448,171 $2,753,222 $4,022,847 $1,442,164
Beginning Cash Position $2,753,222 $4,022,847 $1,442,164 $929,875
Effect Of Exchange Rate Changes $-190,148 $24,860 $0 $0
Changes In Cash $4,885,097 $-1,294,485 $2,580,683 $512,289
Net Issuance Payments Of Debt $-1,789,609 $-405,155 $3,694,935 $5,161,366
Net Long Term Debt Issuance $-1,789,609 $-405,155 $3,694,935 $5,161,366
Long Term Debt Payments $-12,217,108 $-13,740,954 $-8,122,345 $-9,614,228
Long Term Debt Issuance $10,427,499 $13,335,798 $11,817,280 $14,775,595
Net Investment Purchase And Sale $0 $0 $-181,121 $0
Purchase Of Investment $0 $0 $-181,121 $0
Net Intangibles Purchase And Sale $-1,719,765 $-2,099,173 $-622,087 $0
Purchase Of Intangibles $-1,719,765 $-2,099,173 $-622,087 $0
Net PPE Purchase And Sale $-149,159 $-1,994,554 $-937,717 $-4,043,859
Sale Of PPE $0 $15,981 $156,705 $0
Purchase Of PPE $-149,159 $-2,010,536 $-1,094,423 $-4,043,859
Change In Working Capital $6,633,273 $-144,572 $-3,000,488 $-9,854,984
Change In Other Working Capital $187,484 $-59,190 $-105,802 $46,908
Change In Other Current Liabilities $-15,981 $0 $0 $-30,187
Change In Payables And Accrued Expense $-394,501 $247,414 $-6,524,807 $-961,837
Change In Accrued Expense $61,706 $399,236 $-86,121 $30,631
Change In Payable $-456,207 $-151,822 $-6,438,686 $-992,468
Change In Account Payable $-497,492 $-59,782 $-5,269,832 $-1,431,362
Change In Tax Payable $41,285 $-33,886 $-1,139,703 $472,188
Change In Income Tax Payable $41,285 $-33,886 $-1,139,703 $472,188
Change In Prepaid Assets $-3,155,862 $-1,325,856 $-174,906 $-106,098
Change In Inventory $925,139 $-870,389 $-1,909,173 $-1,823,791
Change In Receivables $9,086,994 $1,863,449 $5,714,201 $-7,010,165
Changes In Account Receivables $5,875,937 $2,418,651 $4,593,734 $-3,658,533
Unrealized Gain Loss On Investment Securities $-18,793 $-30,927 $0 $0
Provisionand Write Offof Assets $212,788 $-263,691 $-549,579 $1,440,536
Asset Impairment Charge $1,894,227 $882,227 $1,483,597 $143,240
Deferred Tax $1,641,782 $136,729 $80,054 $-193,995
Deferred Income Tax $1,641,782 $136,729 $80,054 $-193,995
Depreciation Amortization Depletion $3,840,690 $3,575,519 $3,538,377 $2,781,929
Depreciation And Amortization $3,840,690 $3,575,519 $3,538,377 $2,781,929
Depreciation $3,840,690 $3,575,519 $3,538,377 -
Net Foreign Currency Exchange Gain Loss $46,168 $-100,475 $0 $0
Gain Loss On Sale Of PPE $0 $25,748 $27,671 $0
Net Income From Continuing Operations $-12,277,186 $1,993,223 $5,550,392 $8,248,420
Other Non Cash Items - - - -
Fetched: 2026-07-15